JP7705445B2 - Ｓｅｒｃａを調節するキノリン及び疾患を処置するためのその使用 - Google Patents

Ｓｅｒｃａを調節するキノリン及び疾患を処置するためのその使用 Download PDF

Info

Publication number
JP7705445B2
JP7705445B2 JP2023504102A JP2023504102A JP7705445B2 JP 7705445 B2 JP7705445 B2 JP 7705445B2 JP 2023504102 A JP2023504102 A JP 2023504102A JP 2023504102 A JP2023504102 A JP 2023504102A JP 7705445 B2 JP7705445 B2 JP 7705445B2
Authority
JP
Japan
Prior art keywords
mmol
mixture
compound
water
dichloromethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023504102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023534992A5 (enExample
JP2023534992A (ja
Inventor
ダール，ラッセル
Original Assignee
ニューロドン コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/932,832 external-priority patent/US20200347038A1/en
Application filed by ニューロドン コーポレーション filed Critical ニューロドン コーポレーション
Publication of JP2023534992A publication Critical patent/JP2023534992A/ja
Publication of JP2023534992A5 publication Critical patent/JP2023534992A5/ja
Application granted granted Critical
Publication of JP7705445B2 publication Critical patent/JP7705445B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023504102A 2020-07-20 2021-07-19 Ｓｅｒｃａを調節するキノリン及び疾患を処置するためのその使用 Active JP7705445B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/932,832 US20200347038A1 (en) 2014-08-29 2020-07-20 Quinolines that modulate serca and their use for treating disease
US16/932,832 2020-07-20
PCT/US2021/042235 WO2022020261A1 (en) 2020-07-20 2021-07-19 Quinolines that modulate serca and their use for treating disease

Publications (3)

Publication Number Publication Date
JP2023534992A JP2023534992A (ja) 2023-08-15
JP2023534992A5 JP2023534992A5 (enExample) 2024-07-05
JP7705445B2 true JP7705445B2 (ja) 2025-07-09

Family

ID=79729478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504102A Active JP7705445B2 (ja) 2020-07-20 2021-07-19 Ｓｅｒｃａを調節するキノリン及び疾患を処置するためのその使用

Country Status (11)

Country Link
EP (1) EP4037685B9 (enExample)
JP (1) JP7705445B2 (enExample)
CN (1) CN116744928A (enExample)
CA (1) CA3186668A1 (enExample)
DK (1) DK4037685T3 (enExample)
ES (1) ES2968041T3 (enExample)
FI (1) FI4037685T3 (enExample)
HU (1) HUE064550T2 (enExample)
PL (1) PL4037685T3 (enExample)
PT (1) PT4037685T (enExample)
WO (1) WO2022020261A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190151303A1 (en) 2017-02-27 2019-05-23 Rusell Dahl Quinolines that modulate serca and their use for treating disease
US20200347038A1 (en) 2014-08-29 2020-11-05 Russell Dahl Quinolines that modulate serca and their use for treating disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101784533B (zh) * 2007-08-22 2013-08-21 艾博特股份有限两合公司 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途
CN104302640A (zh) * 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
US20170281611A1 (en) * 2014-08-29 2017-10-05 Eiger Biopharmaceuticals, Inc. Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
CN106966973A (zh) * 2017-05-18 2017-07-21 湖北工业大学 N‑苯基‑n‑（2‑甲基‑8‑喹啉基）苯甲酰胺的制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200347038A1 (en) 2014-08-29 2020-11-05 Russell Dahl Quinolines that modulate serca and their use for treating disease
US20190151303A1 (en) 2017-02-27 2019-05-23 Rusell Dahl Quinolines that modulate serca and their use for treating disease

Also Published As

Publication number Publication date
WO2022020261A1 (en) 2022-01-27
FI4037685T3 (fi) 2023-11-27
EP4037685A4 (en) 2022-11-30
DK4037685T3 (en) 2024-01-02
EP4037685B1 (en) 2023-09-20
WO2022020261A9 (en) 2022-09-09
CA3186668A1 (en) 2022-01-27
ES2968041T3 (es) 2024-05-06
CN116744928A (zh) 2023-09-12
PT4037685T (pt) 2023-12-28
HUE064550T2 (hu) 2024-03-28
EP4037685B9 (en) 2024-03-06
PL4037685T3 (pl) 2024-04-02
JP2023534992A (ja) 2023-08-15
EP4037685A1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
US11992487B2 (en) Quinolines that modulate SERCA and their use for treating disease
ES2777123T3 (es) Pirazol para el tratamiento de trastornos autoinmunes
ES2463452T3 (es) Pirimidin-2,4-diaminas y sus usos
ES3041759T3 (en) Fxr small molecule agonist and preparation method therefor and use thereof
US20170281611A1 (en) Quinolines and their use for treating endoplasmic reticulum stress-caused diseases
BR112018068538B1 (pt) Composto, medicamento, e, uso de um composto
KR20260062967A (ko) 사이클릭 포스페이트 화합물
CA2753135A1 (fr) Derives de pyrazolo[1,5-.alpha.]-1,3,5-triazines, leur preparation et leur application en therapeutique
WO2019170150A1 (zh) 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
US11827626B2 (en) Quinolines that modulate SERCA and their use for treating disease
US10772881B2 (en) Quinolines that modulate SERCA and their use for treating disease
WO2021055936A1 (en) Small-molecule inhibitors for the β-catenin/b-cell lymphoma 9 protein−protein interaction
US10383867B2 (en) Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders
WO2021238007A1 (zh) 可诱导prc2蛋白复合物核心亚基降解的双功能化合物和药物组合物及应用
CN110546133A (zh) 抗纤维化化合物
US10383868B2 (en) Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases
CN110191885A (zh) 作为蛋白质聚集调节剂的烷氧基双-杂芳基衍生物
EP4539936A1 (en) Prodrugs of stat3 inhibitors
EP4037685B1 (en) Quinoline that modulate serca and its use for treating disease
HK40099648A (en) Quinolines that modulate serca and their use for treating disease
KR20130100574A (ko) 알콕시페닐프로펜온 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 다약제 내성 억제용 약학적 조성물
WO2026050773A1 (en) Protein kinase inhibitors and uses thereof
WO2025034789A1 (en) Arylbenzoisoxazole compounds as ip6k and ipmk degraders and methods of use thereof
JP2022545763A (ja) Ａ２ａアデノシン受容体アゴニスト活性を有する２－ベンジリデンヒドラジノアデノシン化合物
CN120518582A (zh) 一类并环结构取代的新型cdk12/13共价抑制剂或其药物组合物和应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250627

R150 Certificate of patent or registration of utility model

Ref document number: 7705445

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150